Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients

[1] Hohenberger P(2003)Gastric cancer Lancet 362 305-315

[2] Gretschel S(1995)Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591

[3] Pyrhonen S(1997)Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163-168

[4] Kuitunen T(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anti Cancer Drugs 7 548-557

[5] Nyandoto P(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-1720

[6] Kouri M(2003)Phase I//II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207-2212

[7] Glimelius B(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-1069

[8] Ekström K(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221

[9] Hoffman K(2005)A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen Int J Clin Oncol 10 40-44

[10] Shirasaka T(2003)A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice Gastric Cancer 6 34-39

[1] Hohenberger P(2003)Gastric cancer Lancet 362 305-315

[2] Gretschel S(1995)Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591

[3] Pyrhonen S(1997)Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163-168

[4] Kuitunen T(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anti Cancer Drugs 7 548-557

[5] Nyandoto P(1998)Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715-1720

[6] Kouri M(2003)Phase I//II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207-2212

[7] Glimelius B(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-1069

[8] Ekström K(2008)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221

[9] Hoffman K(2005)A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen Int J Clin Oncol 10 40-44

[10] Shirasaka T(2003)A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice Gastric Cancer 6 34-39